证券代码：688580 证券简称：伟思医疗 公告编号：2023-059 南京伟思医疗科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 11 月 09 日(星期四) 上午 10:00-11:00 投资者可于 2023 年 11 月 02 日(星期四)至 11 月 08 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@vishee.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 26 日发布《2023 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 09 日(星期四)上午 10:00-11:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明 ...

南京伟思医疗科技股份有限公司 注： 1、公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过公司股本总额的 20.00%。上 述任何一名激励对象通过全部在有效期内的股权激励计划获授的公司股票数量累计未超过公司股本总额的 1.00%； 2、以上激励对象不包括公司独立董事、监事、单独或合计持有公司 5%以上股份的股东、公司实际控制 人及其配偶、父母、子女以及外籍员工。 南京伟思医疗科技股份有限公司董事会 2023 年 10 月 25 日 1 2023 年限制性股票激励计划预留授予激励对象名单 （截至授予日） 一、 公司 2023 年限制性股票激励计划（以下简称"本激励计划"）的分配情况 | | 获授的限制 | 获授的限制 | 获授的限 制性股票 | | --- | --- | --- | --- | | 激励对象类别 | 性股票数量 | 性股票数量 | 数量占预 | | | （万股） | 占授予总量 | 留授予日 | | | | 的比例 | 总股本比 | | | | | 例 | | 董事会认为需要激励的其他人员（49 人） | 18.80 | 15.05% | 0.27% | | 合计 | 18.80 ...

上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 上海信公轶禾企业管理咨询有限公司 关于 南京伟思医疗科技股份有限公司 2023 年限制性股票激励计划 预留授予相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二三年十月 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 目 录 | 第一章 | 声 明 1 | | --- | --- | | 第二章 | 释 义 3 | | 第三章 | 基本假设 4 | | 第四章 | 本激励计划履行的审批程序 5 | | 第五章 | 本次限制性股票的授予情况 7 | | | 一、限制性股票预留授予的具体情况 7 | | | 二、本次实施的股权激励计划与股东大会审议通过的激励计划的差异情况..8 | | 第六章 | 本次限制性股票授予条件说明 9 | | | 一、限制性股票授予条件 9 | | | 二、董事会对授予条件成就的情况说明 9 | | 第七章 | 独立财务顾问的核查意见 11 | 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海信公轶禾企业管理咨询有限公司接受委托，担任南京伟思医疗科技股 份有限公司（以下简称"伟思医疗""上市公司"或"公 ...

长江证券承销保荐有限公司 关于南京伟思医疗科技股份有限公司 2023年持续督导工作现场检查报告 上海证券交易所： 根据中国证监会《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所上市公司自律监管指引第11号——持续 督导》等有关法律法规的要求，长江证券承销保荐有限公司（以下简称"长江 保荐"、"保荐机构"）作为正在履行南京伟思医疗科技股份有限公司（以下 简称"伟思医疗"、"上市公司"、"公司"）持续督导工作的保荐机构，本 次现场核查对应的持续督导期间为2023年1月1日至2023年6月30日（以下简称 "本持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关 情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 （五）现场检查内容 公司治理及内部控制、信息披露、独立性、与关联方的资金往来、募集资 金使用情况、关联交易、对外担保、重大对外投资、公司经营状况以及承诺履 行情况等。 长江证券承销保荐有限公司 （二）保荐代表人 梁彬圣、张俊青 （三）现场检查时间 2023年10月18日-2023年10月19日 （四）现场检查人员 梁彬圣 1 （六）现场检查手段 1 ...

Company Overview - Weish Medical was established in 2001 and is headquartered in Nanjing, recognized as a national-level "little giant" enterprise and a high-tech enterprise [2] - The company focuses on the research, development, production, and sales of medical devices, aiming to become a leading supplier in the rehabilitation field in China and a global leader in magnetic stimulation [2] Financial Performance - As of the first half of 2023, total assets amounted to CNY 1,713.27 million, with net assets attributable to shareholders at CNY 1,550.06 million [2] - The company achieved total operating revenue of CNY 219.80 million, a year-on-year increase of 63.87% [2] - Net profit attributable to shareholders reached CNY 70.56 million, up 84.43% year-on-year [2] - The net profit after deducting non-recurring gains and losses was CNY 65.34 million, reflecting a 141.60% increase [3] Market and Business Strategy - The company has adapted to recent anti-corruption policies in the medical industry, which may cause delays in some academic activities but believes the long-term impact on business will be limited [4] - The revenue from the private market has been increasing, and the company is focusing on adjusting strategies to enhance sales directly to end customers [4] - The company has maintained participation in academic exchanges and plans to increase market penetration [5] Product Portfolio - Weish Medical has developed a comprehensive solution for mental rehabilitation, including over 20 products such as transcranial magnetic stimulators and cognitive dysfunction treatment software [8] - The company’s pelvic floor rehabilitation business has seen growth, although its overall contribution has decreased to around 40% of total business, while other areas like neurological and mental rehabilitation have surpassed 50% [8] - The company is expanding its laser and radiofrequency technology platform into aesthetic fields and surgical applications, which are expected to provide new growth points [8] Future Outlook - The company is actively developing core products in the rehabilitation specialty market to enhance its product matrix and support the growth of basic rehabilitation services [8] - The aesthetic energy source product line includes various applications in gynecology, dermatology, and medical beauty, addressing diverse end-user needs [9]

长江证券承销保荐有限公司 关于南京伟思医疗科技股份有限公司 2023年半年度持续督导跟踪报告 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为南 京伟思医疗科技股份有限公司（以下简称"伟思医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据中国证监会《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司 自律监管指引第11号——持续督导》等有关法律法规的要求，出具本持续督导 2023年半年度跟踪报告书。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 | 保荐机构已建立健全并有效执 行了持续督导制度，并制定了 | | | 对具体的持续督导工作制定相应的工作计划 | | | | | 相应的工作计划 | | | 根据中国证监会相关规定，在持续督导工作开 始前，与上市公司或相关当事人签署持续督导 | 保荐机构已与伟思医疗签订 《保荐协议》，该协议明确了 双方在持续督导期间的权利和 | | 2 | 协议，明确双方在持续督导期间的权利义务， | | | | ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of the year reached ¥219,797,179.04, representing a 63.87% increase compared to ¥134,125,295.83 in the same period last year[21]. - Net profit attributable to shareholders was ¥70,557,379.87, an increase of 84.43% from ¥38,256,806.47 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥65,341,062.26, which is a 141.60% increase compared to ¥27,044,968.18 in the previous year[21]. - The net cash flow from operating activities was ¥41,007,501.47, a significant increase from ¥854,899.01 in the same period last year, marking a growth of 4,696.77%[22]. - Basic earnings per share increased to ¥1.0338, up 84.58% from ¥0.5601 in the same period last year[23]. - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 1.5 billion, representing a 20% year-over-year growth[146]. - Net profit attributable to shareholders reached 70.56 million yuan, up 84.43% year-on-year, while the net profit excluding non-recurring gains and losses increased by 141.60% to 65.34 million yuan[92]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users[1]. - User data showed a 15% increase in active users, reaching 10 million by the end of June 2023[146]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - Market expansion efforts have led to a 30% increase in market share in the Asia-Pacific region[146]. - The company is actively pursuing international patent applications under the Patent Cooperation Treaty (PCT) to protect its innovations[13]. Product Development and Innovation - New product launches include a state-of-the-art rehabilitation device, projected to generate an additional RMB 100 million in revenue by year-end[1]. - The introduction of the MyOnvx series products, officially registered as "biostimulation feedback devices," is expected to expand the company's product offerings in the medical device market[13]. - The company is focused on developing advanced technologies in magnetic stimulation, electrical stimulation, electrophysiology, rehabilitation robotics, and laser radiofrequency[29]. - The company launched multiple rehabilitation robot products, including X-walk100, X-walk200/300, and X-locom100, which began sales in 2022, covering full-cycle rehabilitation assessment and training for patients with mobility impairments[31]. - The company is focusing on expanding its investment in the healthcare sector, particularly in medical devices and related technologies[123]. Research and Development - Research and development expenses increased by 30%, focusing on innovative rehabilitation technologies[1]. - The company's R&D expenditure as a percentage of operating revenue decreased to 15.04%, down 9.39 percentage points from 24.43% in the previous year[23]. - Total R&D investment increased by 0.89% to ¥33,053,933.36 compared to ¥32,762,412.42 in the previous year[72]. - The company is actively researching functional and intelligent electrical stimulation technologies to expand its rehabilitation field[62]. - The company has developed a compact high-voltage medical power supply for magnetic stimulation products, capable of continuous output at 150Hz pulse frequency and 6Tesla magnetic field strength[60]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local competitor was completed, enhancing the company's product portfolio and expected to contribute an additional RMB 50 million in annual revenue[1]. - The acquisition of Koryda Laser Company in 2022 has enhanced the company's capabilities in the laser field, particularly in the urinary market, and it is one of the first to obtain Class III medical device registration for holmium laser treatment[49]. - The company is exploring potential acquisitions to further strengthen its market position, with a budget of 200 million allocated for this purpose[146]. - A new strategic partnership was announced, expected to generate an additional 50 million in revenue by the end of 2023[146]. Sustainability and Social Responsibility - The company emphasizes its commitment to sustainability and social responsibility initiatives, aiming to reduce carbon emissions by 15% by 2025[1]. - The management emphasized a focus on sustainability initiatives, aiming to reduce carbon emissions by 40% by 2025[146]. Risk Management - The company has identified potential risks related to supply chain disruptions, which may impact future production capabilities[1]. - The company plans to optimize marketing channels and strengthen dealer management to mitigate risks associated with dealer operations[111]. - The company is closely monitoring industry policies and regulatory changes to adapt its strategic layout accordingly[112]. Shareholder Commitments and Governance - Shareholders and core technical personnel are committed to a 12-month lock-up period from the date of the company's IPO, with an additional 6 months post-departure during which they cannot transfer or delegate management of their pre-IPO shares[163]. - The controlling shareholder and actual controller have committed to a 36-month lock-up period from the IPO date, with an automatic extension of at least 6 months if the stock price falls below the issue price for 20 consecutive trading days[168]. - The company will ensure stable operations and disclose control arrangements if shareholders reduce their pre-IPO shares after the lock-up period[171].

法律意见书 苏同律证字 2023 第 274 号 南京市建邺区贤坤路江岛智立方 C 座 4 层 邮编：210019 电话:+86 25-83304480 传真:+86 25-83329335 江 苏 T PARTNERS 同仁律师事务所 江苏世纪同仁律师事务所 关于南京伟思医疗科技股份有限公司 2021年及2022年限制性股票激励计划之 作废部分已授予尚未归属的限制性股票事项的 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 伟思医疗、公司 | 指 | 南京伟恩医疗科技股份有限公司 | | --- | --- | --- | | 《2021 年激励计 | 損 | 《南京伟思医疗科技股份有限公司 2021年限制性股票 | | 划》 | | 激励计划》 | | 《2022年激励计 | 指 | 《南京伟思医疗科技股份有限公司 2022年限制性股票 | | 划》 | | 激励计划》 | | 《2021 年考核办 | 指 | 《南京伟思医疗科技股份有限公司 2021年限制性股票 | | 法》 | | 激励计划实施考核管理办法》 | | 《2022年考核办 | 指 | 《南京伟思医疗科技股份有 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2023-053 南京伟思医疗科技股份有限公司 第三届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第三届董事会第十四 次会议通知于 2023 年 8 月 18 日以书面方式向全体董事发出。会议于 2023 年 8 月 28 日以现场结合通讯方式在公司会议室召开。本次会议由董事长王志愚先生 召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体监事和高级管理人员 列席了会议。本次会议的召集、召开程序符合《中华人民共和国公司法》等相关 法律、行政法规、规范性文件及《南京伟思医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及其摘要的议案》 经审议，董事会认为：公司 2023 年半年度报告的编制和审议程序符合相关 法律法规及《公司章程》等内部规章制度的规定；公司 2023 年半 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2023-051 南京伟思医疗科技股份有限公司 关于作废部分已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京伟思医疗科技股份有限公司（以下简称"公司"）于2023年8月28日召 开第三届董事会第十四次会议、第三届监事会第十三次会议，审议通过了《关于 作废部分已授予尚未归属的限制性股票的议案》，现将相关事项公告如下： 一、公司2021年限制性股票激励计划已履行的决策程序和信息披露情况 （一）2021 年 1 月 25 日，公司召开第二届董事会第十四次会议，会议审议 通过《关于<公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》《关 于<公司 2021 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提 请股东大会授权董事会办理股权激励相关事宜的议案》等议案。公司独立董事就 公司 2021 年限制性股票激励计划相关议案发表了独立意见。 同日，公司召开第二届监事会第十二次会议，会议审议通过《关于<公司 2021 年限制 ...